Jenny Huang

发表

Structural determinants of human proton-coupled folate transporter oligomerization: role of GXXXG motifs and identification of oligomeric interfaces at transmembrane domains 3 and 6.

L. Matherly, Mike R Wilson, S. Kugel, 2015, The Biochemical journal.

Targeting Nonsquamous Nonsmall Cell Lung Cancer via the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]Pyrimidine Thienoyl Antifolates

L. Matherly, Jenny Huang, Z. Hou, 2016, Molecular Pharmacology.

Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.

R. Advani, Sonali M. Smith, I. Flinn, 2018 .

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

R. Haubrich, M. Kozal, K. Tashima, 2014, The Journal of infectious diseases.

ELISpot and ELISA analyses of human IL-21-secreting cells: Impact of blocking IL-21 interaction with cellular receptors.

B. Zuber, Jenny Huang, N. Ahlborg, 2015, Journal of immunological methods.

PRELIMINARY RESULTS OF AIDS CLINICAL TRIALS GROUP (ACTG) STUDY #149: PHASE II TRIAL OF ABVD CHEMOTHERAPY WITH G-CSF IN HIV INFECTED PATIENTS WITH HODGKIN'S DISEASE (HD): S7

A. Tulpule, Jenny Huang, A. Levine, 1997 .

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

P. Cahn, S. Swindells, J. Mrus, 2020, The New England journal of medicine.

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

A. LaMarca, B. Clotet, C. Katlama, 2012, The Journal of infectious diseases.

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba, J. Zha, L. Rangell, 2014, Clinical Cancer Research.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.

I. Weissman, B. Sikic, C. Takimoto, 2018 .

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

S. Walmsley, M. Murray, Jenny Huang, 2020, AIDS and Behavior.